Hofseth BioCare ASA: THIRD QUARTER 2025 FINANCIAL REPORT

Core Insights - HBC reported total operating revenues of NOK 54.9 million in Q3 2025, down from NOK 67.9 million in the same period last year, attributed to lower commodity prices and a weaker U.S. dollar [1] - The company experienced an EBITDA of NOK -21.1 million, with operational EBITDA at NOK -12.9 million, excluding non-recurring costs [2] - Cash and cash equivalents decreased by NOK 2.6 million, ending at NOK 65.5 million, while total liquidity, including credit facilities, was NOK 67.0 million at quarter-end [3] Financial Performance - The Midsund plant processed 5,288 tonnes of raw material, marking the highest quarterly volume in HBC's history, with a gross margin improvement to 35% from 28% [8] - Human Nutrition B2B sales surged by 200% year-over-year, driven by products like OmeGo® and ProGo®, which also won the NutraIngredients-USA "Healthy Aging" Award [8] - Consumer & Pet Health (B2C) revenues grew by 30%, supported by new European listings and product extensions [8] Product Development and Innovation - HBC focuses on sustainability and optimal utilization of natural resources, converting salmon industry by-products into health-improving ingredients [4] - Key products include ProGo®, OmeGo®, and CalGo® / NT-II®, which have shown various health benefits, including improved iron metabolism and bone health [5][6] - HBC has established academic partnerships and secured patents for its discoveries, leading to the formation of HBC Immunology, which is developing therapeutics for prostate and ovarian cancer [6] Market Position and Strategy - HBC is listed on Oslo Børs under the ticker "HBC" and emphasizes scientific evidence in its product development [7] - The company aims to enhance its equity and liquidity position following a successful private placement in October 2025 [3]